Five instruments were testedfor their capacity to monitor heparin therapy on whole blood at the bedside. The instruments were 512 Coagulation Monitor (Ciba-Corning), Thrombotrack (Nycomed), Automated Coagulation Timer (Hemotec), Hemochron-ACT and Hemochron-APTT (International Technidyne Corporation) .
Heparin therapy must be constantly monitored to reduce the risk of bleeding l ,2 or further thrombosis. 2 -5 Dose modification is usually based upon the activated partial thromboplastin time (APTT)5-7 or less commonly the activated clotting time (ACT). [8] [9] [10] [11] These tests are generally performed in a coagulation laboratory. In certain situations such as outside of routine laboratory hours or when a result is required urgently, the laboratories may be relatively inaccessible. In addition, there is an increasing demand to minimize response times by providing 'point of care' analysis. 12 Intensive care, coronary care and dialysis units have a constant need to monitor and, if necessary, modify heparin therapy. This includes the reversal of heparin therapy after cardiopulmonary bypass. Such clinical units require a compact, robust instrument which will reliably perform either an APTT or ACT on whole blood. The method must be sensitive, reproducible and simple to perform. It should also be free from undue interference from other blood components. If these criteria are met, the bedside method can be standardised against the reference laboratory using regression analysis.
Several portable instruments are currently available which are designed to measure whole blood APTT or ACT and hence may be used in a clinical setting to monitor heparin therapy. METHOD The instruments studied were the 512 Coagulation Monitor (Ciba-Corning), Thrombotrack (Nycomed), Automated Coagulation Timer (Hemotec), Hemochron-ACT (performed on a Hemochron 400) and Hemochron-APTT (performed on a Hemochron 801, International Technidyne Corporation). The results obtained were compared with a plasma APTT performed on the Automated Coagulation Laboratory 300R (Instrumentation Laboratories). In addition antithrombin Ill, fibrinogen, platelet count, and haematocrit were measured to establish whether these parameters contributed to the whole blood APTT.
Blood was collected from fifty subjects following informed consent. Of these, twenty-one were heparinised for haemodialysis, thirteen were intravenously heparinised as therapy for deep venous thrombosis, pulmonary embolus or acute myocardial infarction, seven were subcutaneously heparinised as a prophylactic measure. The final nine subjects were not receiving heparin therapy.
The sample collected was venous blood. Where an in-dwelling catheter was used for collection (such as in the haemodialysis patients) the first 10 ml of blood was discarded. 13 Fresh whole blood was used to perform analyses on the 512 Coagulation Monitor, the Hemochron-ACT and the Hemochron-APTT (only forty samples were tested with the Hemochron-APTT as the distributors could not supply sufficient assay tubes). Citrated whole blood was used to perform analyses on the Thrombotrack and the Automated Coagulation Timer. For these tests nine volumes of blood were anticoagulated with one volume of 3.8% trisodium citrate. A platelet count and haematocrit were performed on whole blood anticoagulated with Ky EDTA using a STKS analyser (Coulter Electronics).
To obtain platelet-poor plasma, the citrated sample was centrifuged for ten minutes at 3300 G and 4°C and the plasma harvested. The plasma APTT and fibrinogen were performed immediately on the ACL300R according to manufacturer's instructions and the remaining plasma frozen at -20°C for later measurement of antithrombin III and heparin. These assays were performed on the ACL300R using chromogenic assay kits supplied by Instrumentation Laboratories. Where an instrument was not supplied with a reagent to perform the APTT (ACL300R, Thrombotrack and Automated Coagulation Timer) the reagent used was Actin FSL (Dade).
RESULTS
The results obtained with each of the instruments are shown as a function of the reference APTT method in Figures 1-5. The Pearson Correlation Coefficients for each of the instruments in comparison with plasma heparin level and reference APTT are shown in Table 1 . All results were analysed using the Minitab statistical program.
The 512 Coagulation Monitor did not detect an endpoint for 16 out of 50 (32%) of the samples, while the Automated Coagulation Timer did not detect an endpoint on 6 out of 50 (12%) occasions. Using multiple regression analysis the result obtained on the 512 Coagulation Monitor was shown to be significantly related to the haematocrit (P = 0.006) and fibrinogen (P = 0.041). The instruments were not affected by antithrombin III levels or platelet count. Reproducibility studies were not performed because three of the instruments required fresh whole blood which would have required multiple venepuncture of the subjects. The precision of each of the instruments was derived by calculating the standard deviation of the observed result from that predicted by linear regression of the observed data ( Table 2) .
It should be pointed out that the APTT result produced by the 512 Coagulation Monitor is not real time, but rather a calculated 'plasma APTT' derived from the whole blood APTT.
DISCUSSION
The use of whole blood clotting tests to monitor heparin therapy at the bedside is desirable in several situations, provided the test performed is an accurate representation of the degree of anticoagulation. 2 • 9 The results obtained indicate significantly higher mean reference APTT than the successful samples (P = 0.005) and the mean fibrinogen level of the failures tended to be lower, although not to a significant extent (P = 0.071). However, the demarcation between failure and success was not as distinct as that seen with the 512 Coagulation Monitor. The results obtained indicate that apart from the Hemochron-ACT, all instruments would be adequate in assessing reversal of heparin therapy. Whole blood testing carries the possibility of platelet activation and a consequent anti-heparin effect due to platelet factor 4 release. 14 This possibility was not examined in this study. As these instruments are aimed at a clinical setting, other aspects of their function also needed to be considered. All instruments were simple to use, although using the Automated Coagulation Timer and Thrombotrack required some pipetting skills which we have found to be unsuitable for nonlaboratory staff. The Hemochron-ACT, Hemochron-APTT and 512 Coagulation Monitor used fresh whole blood as test material which meant that the assay had to be performed immediately. However, of these three, only the Hemochron-APTT could accommodate duplicate analysis (in this study, the shortage of assay tubes prevented duplicate analyses). The advantages and disadvantages of duplicate analyses of the APTT have been well documented. 15 • 16 However, the provision of duplicate test wells on the Hemochron-APTT instrument is a useful feature. The Automated Coagulation Timer and Thrombotrack used citrated whole blood as test material, which meant that multiple assays could be performed on the one sample if necessary. In addition, the latter two instruments could be adapted to virtually any APTT reagent. This is a significant advantage, as the differing sensitivities of APTT reagents to heparin 6 ,17.20 can make the comparison of two methods difficult to interpret and lead to inappropriate dose modification. 17 ,21 Another important feature of the Thrombotrack and the 512 Coagulation Monitor is their ability to measure prothrombin time and therefore monitor warfarin therapy.
The Hemochron-ACT, Hemochron-APTT and 512 Coagulation Monitor had a back-up battery, which meant that the need for a power outlet was optional. The Automated Coagulation Timer and Thrombotrack required an AC outlet. All were relatively portable, although the Automated Coagulation Timer was somewhat cumbersome (in this trial, the Automated Coagulation Timer and Thrombotrack testing was performed in a laboratory, as anticoagulated blood was used).
In summary, this trial has shown the most suitable instrument of those tested for bedside heparin monitoring is the Hemochron-APTT. The results obtained with this instrument were adequate, it was not complex to operate, it was quite portable, and did not require an AC outlet. The Hemochron-APTT used whole blood which was citrated, activated and subsequently recalcified in the one assay tube. In contrast, the Hemochron-ACT used activated whole blood which had not been decalcified and hence was an activated clotting time rather than an APTT. The usefulness ofthe activated clotting time in monitoring heparin Anaesthesia and Intensive Care, Vol. 19 . No. 4. November, 1991 therapy is debatable. 9 . 11 The Automated Coagulation Timer and Thrombotrack produced adequate results, but their operation was relatively complex. These two instruments are probably best suited to a laboratory rather than as bedside instrumentation. The 512 Coagulation Monitor was the easiest to use, but the results obtained showed that this instrument does not have sufficient range to measure APTTs over the entire therapeutic range. In addition, the results obtained on this instrument were shown to be significantly affected by haematocrit and fibrinogen. This effect is almost certainly due to the fact that this instrument relies on the slowing of the capillary action of whole blood to detect a clot, while the four other instruments detect a clot by its interference with a magnetic stirrer or a mechanical arm. It is important that users of such instruments are aware that other factors such as lupus anticoagulants 22 and acquired coagulation factor-specific inhibitors 23 can prolong the APTT and complicate interpretation of heparin dosage.
